Mucosal immunization with a killed whole-cell pneumococcal vaccine, given with enterotoxinrelated adjuvants, has been shown to confer multi-serotype protection against colonization of the nasopharynx and middle ear in mice. However, because novel mucosal immunization strategies may be difficult to implement, here we evaluated subcutaneous injection. Strain RM200 was engineered to be capsule-negative, autolysin-negative, and to express a non-toxic mutant pneumolysoid. Liter-scale and 60-L Good Manufacturing Practice (GMP) cultures were grown in bovine-free soy-based medium, killed with chloroform or beta-propiolactone, and injected into C57Bl/6 mice without or with aluminum adjuvant. The adjuvant Al(OH) 3 strongly increased responses, particularly if pre-treated with phosphate. Protection was found in several tested model infections: nasal colonization with a serotype 6B strain and fatal aspiration-sepsis with strains of serotype 3 and 5. Protection against colonization was mechanistically dependent on the presence of CD4+ T cells at the time of challenge; in contrast, in the type 3 aspiration-sepsis model, CD4+ T cells were not required for protection at the time of challenge, suggesting that antibody alone was sufficient to protect against death in this model. Rabbits receiving sequential intramuscular injections in a pilot toxicity study displayed local reactogenicity at injection sites but no clinical signs. The rabbit antiserum thus produced was active in an in vitro phagocytic killing assay and passively protected mice in the type 3 aspiration-sepsis model. Approval is being sought for human trials of this vaccine.
The pneumococcal type 1 pilus, which is present in 25 to 30% of clinical isolates, has been associated with increased adherence and inflammatory responses and is being evaluated as a potential vaccine candidate. Here we show that expression of the pilus is bistable as a result of the molecular interaction between the transcription activator RrlA and a structural component of the pilus called RrgA. Sampling various clinical pneumococcal isolates that harbor the type 1 pilus-encoding islet, we show that distinct populations of cells can be identified with either undetectable or prominent pilus expression. When these two populations are separated and regrown in liquid medium, they are phenotypically different: the nonexpressing population reverts to the previous bimodal distribution, whereas the expressing population retains the same high level of pilus expression. Controlled exogenous expression of the regulatory pilus gene rlrA in a strain from which the endogenous version has been deleted increases pilus expression steadily, suggesting that the bistable expression of the pilus observed in wild-type cells is dependent on the native rlrA promoter. Finally, we demonstrate that RrgA is a negative regulator of pilus expression and that this repression is likely mediated through direct interaction with RlrA. We conclude that type 1 pilus expression in pneumococcus exhibits a bistable phenotype, which is dependent upon the molecular interplay between the RlrA and RrgA proteins. We suggest that this flexibility in expression may assist adaptation to a range of immune conditions, such as evasion of antipilus antibodies, within potential hosts.
Background:The pneumococcal pilus is associated with increased inflammation. Results: A 49-amino acid region of the pilus protein RrgA activates TLR2 and is associated with increased inflammation and virulence. Conclusion:The pneumococcal pilus is a TLR2 agonist; RrgA is a key component. Significance: A better understanding of the pilus in bacterial pathogenesis is crucial for the development of novel strategies against this pathogen.
Objective: Heart failure (HF) has become an increasingly frequent cause of hospital admission and carries a poor prognosis. There is a paucity of data in Indo-Asians particularly in Bangladesh on characteristics of heart failure patients. The purpose of this study was to determine the etiological factors and co-morbidity of hospitalized heart failure patients. Method: A hospital based cross sectional study was done at a tertiary cardiac hospital in Dhaka city. Hospital medical records of 14009 patients admitted between January 2005 and August 2006 were reviewed and 1970 patients with the diagnosis of HF were identified. Relevant etiological information and socio demographic data were abstracted from the hospital record files. Result: About one-seventh of total hospital admitted patient had HF. Mean age (SD) was 54.1 (15.3) years. Majority (35.79%) had ischaemic heart disease (IHD) as the principal etiological factor but this frequently coexisted with a history of hypertension (46.8%). Hypertension was considered the primary risk factor of HF in 29.14% of cases. Hypertension alone and in coexistence with other etiology was found in 48.07% (947) cases. Diabetes Mellitus (DM) co-existed with IHD in 41.4% (292) and it (32.64%) was found more prevalent in Dilated Cardiomyopathy (DCM) patient with HF. Conclusions: The mean age of hospitalized HF patients is remarkably lower than other related studies done abroad. The single most common etiology for HF is ischemic heart disease in this population. Hypertension is the most common risk factor. Measures to prevent ischaemic heart disease and control of risk factors are essential to prevent premature onset of HF. DOI: 10.3329/jbcps.v28i1.4640 J Bangladesh Coll Phys Surg 2010; 28: 24-29
Expression of the pneumococcal type 1 pilus is bistable and positively regulated by the transcription factor RlrA. RlrA is also known to positively control its own expression. Here we present evidence that bistable expression of the type 1 pilus is mediated by the positive-feedback loop controlling rlrA expression.
Newer data platforms offer increased opportunity to share multidimensional health data with research participants, but the preferences of participants for which data to receive and how is evolving. Our objective is to describe the preferences and expectations of participants for the return of individual research results within Project Baseline Health Study (PBHS). The PBHS is an ongoing, multicenter, longitudinal cohort study with data from four initial enrollment sites. PBHS participants are recruited from the general population along with groups enriched for heart disease and cancer disease risk. Cross-sectional data on return of results were collected in 2017–2018 from an (1) in-person enrollment survey (n = 1,890), (2) benchmark online survey (n = 1,059), and (3) participant interviews (n = 21). The main outcomes included (1) preferences for type of information to be added next to returned results, (2) participant plans for sharing returned results with a non-study clinician, and (3) choice to opt-out of receiving genetic results. Results were compared by sociodemographic characteristics. Enrollment and benchmark survey respondents were 57.1% and 53.5% female, and 60.0% and 66.2% white, respectively. Participants preferred the following data types be added to returned results in the future: genetics (29.9%), heart imaging, (16.4%), study watch (15.8%), and microbiome (13.3%). Older adults (OR 0.60, 95% CI: 0.41–0.87) were less likely to want their genetic results returned next. Forty percent of participants reported that they would not share all returned results with their non–study clinicians. Black (OR 0.64, 95% CI 0.43–0.95) and Asian (OR 0.47, 95% CI 0.30–0.73) participants were less likely, and older participants more likely (OR 1.45–1.61), to plan to share all results with their clinician than their counterparts. At enrollment, 5.8% of participants opted out of receiving their genetics results. The study showed that substantial heterogeneity existed in participant’s preferences and expectations for return of results, and variations were related to sociodemographic characteristics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.